Your Patient Needs Cefepime — and Your Pharmacy Is Out

You've diagnosed a serious bacterial infection — pneumonia, a complicated UTI, febrile neutropenia — and Cefepime is the right call. But your hospital pharmacy is short, or your patient is being discharged to home infusion and their outpatient pharmacy can't source it.

This scenario has become increasingly common as the Cefepime shortage persists into 2026. As a prescriber, you're not just managing the infection — you're managing the supply gap. This guide provides practical steps to help your patients access Cefepime or a suitable alternative when supply is constrained.

Current Cefepime Availability

Cefepime injection remains on the ASHP Drug Shortage list in 2026. B. Braun has reported manufacturing delays, and other generic manufacturers have experienced intermittent supply disruptions. The shortage has been ongoing, with roots stretching back to the early 2010s and recurring episodes of limited availability.

Key supply observations:

• Pre-mixed IV solutions have been disproportionately affected in some distribution channels
• Powder vials (500 mg, 1 g, 2 g) may be more consistently available but still face constraints
• Home infusion and outpatient services often experience supply gaps more acutely than inpatient pharmacies with GPO contracts
• Regional variation is significant — a facility 50 miles away may have stock when yours doesn't

For the full shortage background, see: Cefepime shortage: What providers and prescribers need to know in 2026.

Why Patients Can't Find It on Their Own

Understanding your patient's perspective helps you provide better support:

• Cefepime isn't a retail pharmacy drug. Patients can't simply go to CVS or Walgreens to fill a Cefepime prescription. It's dispensed through hospital pharmacies, infusion centers, and specialty/home infusion pharmacies — systems that patients often don't know how to navigate.
• The shortage isn't transparent. Patients don't have access to ASHP or FDA shortage databases, and they may not understand why a drug their doctor prescribed simply isn't available.
• Insurance adds complexity. Even when Cefepime is found, insurance coverage for outpatient IV therapy may require prior authorization, medical necessity documentation, or coordination with a specific infusion provider.
• Cost is a barrier. Cash prices for Cefepime range from $200 to $600+ per course. Patients without adequate insurance may be unable to afford treatment without assistance.

What Providers Can Do: 5 Actionable Steps

Step 1: Check Institutional Supply First

Before your patient leaves the building, confirm Cefepime availability with your inpatient pharmacy. If your facility has stock, completing as much of the IV course as possible before discharge ensures the patient gets treatment while supply is accessible.

If your pharmacy is short, ask about expected restock dates. Pharmacy staff often have visibility into upcoming shipments.

Step 2: Use Medfinder to Locate Supply

Medfinder for Providers helps clinicians search for medication availability across pharmacy networks. Use it to identify nearby facilities that have Cefepime in stock — including specialty infusion pharmacies, independent pharmacies, and other hospital systems.

Share the patient-facing version (medfinder.com) with your patients so they can continue checking availability on their own.

Step 3: Coordinate with Home Infusion Services

For patients transitioning to outpatient IV therapy, home infusion companies are critical partners. These companies specialize in sourcing and delivering IV medications and often have access to supply channels that standard pharmacies don't.

Key actions:

• Initiate the home infusion referral early — ideally 24-48 hours before anticipated discharge
• Provide the infusion company with the full treatment plan (dose, frequency, duration, monitoring requirements)
• Ask the infusion company about Cefepime stock before finalizing the prescription
• Have a backup plan (see Step 4) in case the infusion company can't source Cefepime

Step 4: Identify and Document Alternative Agents

When Cefepime is unavailable, having a pre-determined alternative ready prevents treatment delays. Document your clinical reasoning for the switch in the patient's chart.

Common alternatives based on clinical scenario:

• Febrile neutropenia: Piperacillin/Tazobactam (4.5 g IV every 6 hours) or Meropenem (1-2 g IV every 8 hours)
• Hospital-acquired/ventilator-associated pneumonia: Piperacillin/Tazobactam or Meropenem, guided by antibiogram
• Complicated UTI: Meropenem (if ESBL-producing organisms suspected) or Ceftazidime (if Pseudomonal coverage is the primary concern)
• Complicated intra-abdominal infections: Piperacillin/Tazobactam provides anaerobic coverage that Cefepime + Metronidazole would offer

For a patient-accessible comparison: Alternatives to Cefepime.

Step 5: Address Cost and Access Barriers Proactively

Don't assume your patient can afford outpatient IV therapy. Ask about their insurance coverage and connect them with resources:

• Prior authorization support: Include shortage documentation with any prior auth submission — many payers expedite approvals during documented shortages
• Patient assistance programs: NeedyMeds and RxAssist maintain databases of financial assistance for injectable medications
• Hospital charity care: For uninsured patients treated inpatient, most hospitals have financial assistance programs that cover medications administered during the stay
• Social work referral: A case manager or social worker can help patients navigate the financial and logistical aspects of outpatient IV therapy

For a patient-facing cost guide: How to save money on Cefepime in 2026.

Alternative Agents: Quick Reference

The table below summarizes key alternative agents for common Cefepime indications:

• Piperacillin/Tazobactam (Zosyn): Broad gram-negative + anaerobic coverage. Good for pneumonia, intra-abdominal, polymicrobial infections. Watch: also subject to shortages; AKI monitoring with Vancomycin.
• Meropenem (Merrem): Broadest spectrum. ESBL/AmpC coverage. Reserve for resistant organisms per stewardship. Higher cost.
• Ceftazidime (Fortaz): Anti-Pseudomonal activity. Weaker gram-positive coverage. May need supplementation. Available as IV/IM.
• Imipenem/Cilastatin (Primaxin): Broad spectrum including anaerobes. Slightly higher seizure risk at high doses. Use for polymicrobial/resistant infections.

Always verify alternatives against your institution's antibiogram and consult with your antimicrobial stewardship pharmacist.

Workflow Tips for Managing the Shortage

• Build shortage protocols into your EHR. Work with pharmacy and IT to create order sets that flag Cefepime availability and suggest pre-approved alternatives.
• Communicate with patients early. If you anticipate a supply issue, explain it to the patient before discharge. Set expectations about potential delays and alternative plans.
• Track ASHP and FDA updates. Subscribe to ASHP Drug Shortage alerts to stay informed about supply changes.
• Coordinate across departments. Emergency medicine, oncology, pulmonary/critical care, and infectious disease all rely on Cefepime — institutional allocation decisions should involve stakeholders from each department.
• Document thoroughly. When switching from Cefepime due to shortage, document the shortage as the reason for the change. This protects both the patient and the provider if outcomes are questioned.

Final Thoughts

Drug shortages shouldn't force you to compromise patient care. With proactive planning, early coordination with pharmacy and home infusion services, and tools like Medfinder for Providers, you can navigate the Cefepime shortage while keeping your patients on track with effective treatment.

For patient-facing resources you can share: How to find Cefepime in stock near you and Cefepime shortage update for patients.

For more on the cost-saving resources you can point patients to: How to help patients save money on Cefepime.